CJC-1295
A modified GHRH(1-29) analog engineered for improved stability against enzymatic breakdown, intended to produce a pulsatile GH release pattern closer to natural physiology.
Research status: Human pharmacokinetic studies exist; often paired with a GHRP in research literature.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Selected references
- Journal of Clinical Endocrinology & Metabolism · 2006 Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
- Journal of Clinical Endocrinology & Metabolism · 2006 Once-Daily Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone (GHRH) Analog, Normalizes Growth in the GHRH Knockout Mouse
- European Journal of Endocrinology · 1998 Ipamorelin, the first selective growth hormone secretagogue
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
Related in Growth Hormone (GHRH)